An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

A new thesis from Karolinska Institutet aims to advance our understanding of the bidirectional relationship between ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...